CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009

Share Article

With its Investigational New Drug (IND) application cleared by the U.S. Food and Drug Administration (FDA), Immunovative Therapies, Ltd. (ITL) announced that Phase I/II clinical trials of its experimental CryoStim™ cancer vaccine product for the treatment of advanced metastatic solid tumors will begin September, 2009. CryoStim™ is an individualized cancer vaccine that is made inside the body by combining the experimental AlloStim™ drug with the killing of a selected tumor cells by the minimally invasive procedure called cryoablation. AlloStim™ contains living immune cells attached to microbeads designed to stimulate and direct the human immune system to directly kill cancer cells wherever they reside in the body. Phase I/II clinical trials will be conducted at its new clinical research subsidiary in Carlsbad, California.

Dr. Berger sitting at he feet of Drue and James to the right.

CryoStim™ represents a completely novel approach for therapeutic cancer design

Past News Releases

RSS

Immunovative Therapies Ltd. (http://www.immunovative.co.il.) has announced that its CryoStim™ experimental product has been cleared by the FDA to begin human clinical trials. Immunovative Therapies, Ltd. experimental products are based upon "Mirror Effect™" technology (patents issued and pending) which is designed to provide the same anti-tumor effect that has been proven to be curative in allogeneic bone marrow transplant (BMT) procedures without the lethal toxicity or need for a matched donor.

Immunotherapy is a new modality for cancer treatment which holds great promise for becoming a curative therapy with minimal toxicity. It works together with or replaces current treatment methods. The human immune system is capable of seeking out and destroying cancers cells wherever they reside in the body. Harnessing the power of the immune system holds the greatest potential for winning the battle against cancer.

"CryoStim™ represents a completely novel approach for therapeutic cancer design," says Dr. Michael Har-Noy, CEO and Chief Technical Officer. "Current therapies are not capable of eliminating every last cancer cell in the body and thus tumor recurrence is a common problem. If our experimental therapy is successful it would be possible to not only eliminate every last tumor cells, but also for the immune system to remember the tumor in order to prevent recurrence."

Details about this cancer vaccine trial can be found at http://www.immunocare.net and at clinicaltrials.gov: NCT00861107. View complete details on products, clinical trials and scientific literature at the company website.

About Immunovative:
Immunovative Therapies, Ltd. (ITL) is an Israeli-based biopharmaceutical company with US facilities in Carlsbad, California. Founded in May 2004 with financial support from Israel's Office of the Chief Scientist, ITL is a graduate of the Misgav Venture Accelerator, a member of the world renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate bioengineered living immune cells as the active ingredients for treatment of cancer, autoimmune and infectious disease.

Contact:
Thu Bui at 760-444-9040

In the Pacific Northwest contact Alan F. Hall JD at 425-774-9566

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alan F. Hall

Michael Berger MD
Immunovative Therapies Ltd.
760-444-9040
Email >
Visit website